艾曲波帕治疗伴有严重血小板减少的慢性粒细胞白血病。法语骨髓增生症小组（GFM）研究

IF 12.8 1区医学 Q1 HEMATOLOGY

Leukemia Pub Date : 2024-09-12 DOI:10.1038/s41375-024-02402-8

Florence Rabian, Sylvie Chevret, Bérengère Gruson, Sylvain Thépot, Anouk Walter-Petrich, Thorsten Braun, Norbert Vey, José Miguel Torregrosa-Diaz, Pierre Peterlin, Andrea Toma, Maud D’Aveni, Jacques Delaunay, Laurence Legros, Nathalie Droin, Fatiha Chermat, Daniel Lusina, Lionel Adès, Rosa Sapena, Eric Solary, Pierre Fenaux, Raphael Itzykson

{"title":"艾曲波帕治疗伴有严重血小板减少的慢性粒细胞白血病。法语骨髓增生症小组（GFM）研究","authors":"Florence Rabian, Sylvie Chevret, Bérengère Gruson, Sylvain Thépot, Anouk Walter-Petrich, Thorsten Braun, Norbert Vey, José Miguel Torregrosa-Diaz, Pierre Peterlin, Andrea Toma, Maud D’Aveni, Jacques Delaunay, Laurence Legros, Nathalie Droin, Fatiha Chermat, Daniel Lusina, Lionel Adès, Rosa Sapena, Eric Solary, Pierre Fenaux, Raphael Itzykson","doi":"10.1038/s41375-024-02402-8","DOIUrl":null,"url":null,"abstract":"Severe thrombocytopenia (<50 ×109/L) occurs in 10–30% of Chronic Myelomonocytic Leukemias (CMML) and leads to significant mortality through increased risk of bleeding and disease progression [1]. Its management is ill codified [2].The thrombopoietin receptor agonist Eltrombopag improves platelet counts in lower-risk myelodysplastic syndromes [3]. Its activity in CMML has been investigated in retrospective case series of up to eleven patients [4,5,6], or as part of a phase I MDS trial [7].","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":null,"pages":null},"PeriodicalIF":12.8000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des Myélodysplasies (GFM) study\",\"authors\":\"Florence Rabian, Sylvie Chevret, Bérengère Gruson, Sylvain Thépot, Anouk Walter-Petrich, Thorsten Braun, Norbert Vey, José Miguel Torregrosa-Diaz, Pierre Peterlin, Andrea Toma, Maud D’Aveni, Jacques Delaunay, Laurence Legros, Nathalie Droin, Fatiha Chermat, Daniel Lusina, Lionel Adès, Rosa Sapena, Eric Solary, Pierre Fenaux, Raphael Itzykson\",\"doi\":\"10.1038/s41375-024-02402-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Severe thrombocytopenia (<50 ×109/L) occurs in 10–30% of Chronic Myelomonocytic Leukemias (CMML) and leads to significant mortality through increased risk of bleeding and disease progression [1]. Its management is ill codified [2].The thrombopoietin receptor agonist Eltrombopag improves platelet counts in lower-risk myelodysplastic syndromes [3]. Its activity in CMML has been investigated in retrospective case series of up to eleven patients [4,5,6], or as part of a phase I MDS trial [7].\",\"PeriodicalId\":18109,\"journal\":{\"name\":\"Leukemia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2024-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41375-024-02402-8\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41375-024-02402-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

10%-30%的慢性粒细胞白血病（CMML）会出现严重血小板减少症（50 ×109/L），并因出血和疾病进展风险增加而导致大量死亡[1]。血小板生成素受体激动剂 Eltrombopag 可改善低危骨髓增生异常综合征患者的血小板计数[3]。在多达 11 例患者的回顾性病例系列中[4,5,6]，或作为 MDS I 期试验的一部分[7]，研究了 Eltrombopag 对 CMML 的活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des Myélodysplasies (GFM) study

查看原文本刊更多论文

Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des Myélodysplasies (GFM) study

Severe thrombocytopenia (<50 ×10⁹/L) occurs in 10–30% of Chronic Myelomonocytic Leukemias (CMML) and leads to significant mortality through increased risk of bleeding and disease progression [1]. Its management is ill codified [2].

The thrombopoietin receptor agonist Eltrombopag improves platelet counts in lower-risk myelodysplastic syndromes [3]. Its activity in CMML has been investigated in retrospective case series of up to eleven patients [4,5,6], or as part of a phase I MDS trial [7].

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Leukemia 医学-血液学

CiteScore

18.10

自引率

3.50%

发文量

270

审稿时长

3-6 weeks

期刊介绍： Title: Leukemia Journal Overview: Publishes high-quality, peer-reviewed research Covers all aspects of research and treatment of leukemia and allied diseases Includes studies of normal hemopoiesis due to comparative relevance Topics of Interest: Oncogenes Growth factors Stem cells Leukemia genomics Cell cycle Signal transduction Molecular targets for therapy And more Content Types: Original research articles Reviews Letters Correspondence Comments elaborating on significant advances and covering topical issues